diabetes

Poxel posts phase 3 diabetes data ahead of approval decision
Poxel posts phase 3 diabetes data ahead of approval decision
Fierce Biotech
Poxel
diabetes
clinical trials
imeglimin
Japan
Flag link:
Could MiniMed 770G’s Approval Boost Medtronic’s Position in Diabetes?
Could MiniMed 770G’s Approval Boost Medtronic’s Position in Diabetes?
Medical Devices and Diagnostics Industry
diabetes
Medtronic
MiniMed 770G
insulin pumps
Flag link:
Novo launches type 2 diabetes pill in UK after NICE waives review
Novo launches type 2 diabetes pill in UK after NICE waives review
Pharmaforum
Novo Nordisk
UK
type 2 diabetes
diabetes
Rybelsus
semaglutide
NICE
Flag link:
Biocon and Mylan Launch Semglee; Biosimilar, Interchangeable Status Are Sought
Biocon and Mylan Launch Semglee; Biosimilar, Interchangeable Status Are Sought
Center for Biosimilars
Biocon
Mylan
Semglee
generics
insulin
diabetes
biosimilars
Flag link:
ESC 2020 – Farxiga impresses in chronic kidney disease
ESC 2020 – Farxiga impresses in chronic kidney disease
EP Vantage
ESC
Farxiga
chronic kidney disease
diabetes
clinical trials
AstraZeneca
Flag link:
Study: Type 2 Diabetes Treatments May Be More Effective When Combined
Study: Type 2 Diabetes Treatments May Be More Effective When Combined
BioSpace
diabetes
type 2 diabetes
FGF21
GLP-1 agonist
Flag link:
FDA pulls J&J's Invokana boxed warning after reviewing amputation risks—but the sales damage is done
FDA pulls J&J's Invokana boxed warning after reviewing amputation risks—but the sales damage is done
Fierce Pharma
JNJ
Invokana
diabetes
amputation
black box
Flag link:
Novo Nordisk: Prevention, digital tools and collaboration to define the future of diabetes
Novo Nordisk: Prevention, digital tools and collaboration to define the future of diabetes
Pharmaforum
Novo Nordisk
diabetes
digital pharma
digital medicine
Flag link:
25% of diabetes patients rationing treatments amid pandemic, survey finds
25% of diabetes patients rationing treatments amid pandemic, survey finds
Beckers Hospital Review
diabetes
pandemic
COVID-19
patients
Flag link:
Boehringer and Lilly’s Jardiance Hits Mark in Decreasing Risk of Death in Heart Failure
Boehringer and Lilly’s Jardiance Hits Mark in Decreasing Risk of Death in Heart Failure
BioSpace
Boehringer Ingelheim
Eli Lilly
Jardiance
heart failure
diabetes
clinical trials
Flag link:
Drug lobby sues Minnesota over insulin-pricing law
Drug lobby sues Minnesota over insulin-pricing law
Beckers Hospital Review
Minnesota
regulatory
insulin
drug pricing
diabetes
PhRMA
Flag link:
FDA urged to increase safety warnings on common diabetes drug
FDA urged to increase safety warnings on common diabetes drug
Beckers Hospital Review
Public Citizen
diabetes
citizen petitions
SGLT2 inhibitor
type 1 diabetes
Flag link:
Mylan, seeking to market Victoza generic, convinces panel to start up patent review
Mylan, seeking to market Victoza generic, convinces panel to start up patent review
Fierce Pharma
Mylan
patents
generics
Novo Nordisk
Victoza
diabetes
Flag link:
Novaremed gets FDA nod for phase 2 trial of NRD135S.E1 for PDPN
Novaremed gets FDA nod for phase 2 trial of NRD135S.E1 for PDPN
Pharmaceutical Business Review
Novaremed
FDA
clinical trials
NRD135S.E1
diabetes
painful diabetic peripheral neuropathy
Flag link:
Evoke Pharma finally lands approval for lead and only drug
Evoke Pharma finally lands approval for lead and only drug
Endpoints
Evoke Pharma
FDA
diabetic gastroparesis
diabetes
Gimoti
Flag link:
Study: Pfizer's Experimental Diabetes Drug Robustly Reduces Weight and Glucose
Study: Pfizer's Experimental Diabetes Drug Robustly Reduces Weight and Glucose
BioSpace
ADA
diabetes
Pfizer
PF-06882961
Flag link:
ADA: Merck, Pfizer's Steglatro rings up CV safety win but still lags heart-helping peers
ADA: Merck, Pfizer's Steglatro rings up CV safety win but still lags heart-helping peers
Fierce Pharma
ADA
diabetes
Merck
Pfizer
Steglatro
Flag link:
ADA: AstraZeneca's diabetes-fighter Farxiga cuts risk of fast decline in kidney function
ADA: AstraZeneca's diabetes-fighter Farxiga cuts risk of fast decline in kidney function
Fierce Pharma
AstraZeneca
Farxiga
chronic kidney disease
ADA
diabetes
Flag link:
Why MannKind Stock Crushed it Monday
Why MannKind Stock Crushed it Monday
Motley Fool
MannKind
ADA
diabetes
insulin
Afrezza
inhaled insulin
Flag link:
Abbott's Bluetooth-Enabled Glucose Monitor Finally Clears FDA Hurdle
Abbott's Bluetooth-Enabled Glucose Monitor Finally Clears FDA Hurdle
Motley Fool
Abbott Labs
FDA
blood glucose monitoring
devices
diabetes
Freestyle Libre 2
Flag link:

Pages